KraneShares MSCI All China Health Care Index ETF (KURE)

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.

Investors in mainland China are rapidly unwinding their stock-index hedges, in an indication that a possible end to Chengdu’s lockdown and policies to stabilize the yuan will lead to a near-term market rally, reported 

Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.

These ETFs beat the S&P 500 in April 2025’s turbulent market. Learn how TOLZ, VIXY, and KURE can help stabilize your investment strategy.

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

China's NPC meeting has sparked optimism in the market, with Chinese stocks and bonds rallying. Investors are hopeful for growth targets but remain skeptical.